

**Summary of Health Consumer Organisations supported by Medicines Australia Member Companies**  
**For the period: 01 Jan 2018 to 31 Dec 2018**

**Company: GlaxoSmithKline Australia Pty Ltd**

Name of Health Consumer Organisation	Description of and/or purpose of support	Nature of support (monetary value or equivalent) or description of non-financial support
Allergy & Anaphylaxis Australia	<p>Financial support provided to Allergy and Anaphylaxis Australia (A&amp;AA) to update parent resources.</p> <p>The update includes converting existing Camp Booklets for parents, schools and camp facilities into an online e-book (available in both Apple and Android). Having an e-book specific to camp preparation and management of severe allergy allows improved understanding and knowledge of practices that increases safety at camps. In addition, recent changes to the ASCIA Action Plans requires existing resources to be updated and free online training made available. Funding is also to be used to employ a Social Media and Communications Coordinator who will assist in the promotion of this e-book and other educational resources</p>	\$ 25,000.00
Asthma Australia	<p>Donation of 1,182 Ellipta, 1,096 Accuhaler, 2,156 MDI, 426 Haleraid 120 and 411 Haleraid 200 placebo inhaler devices</p> <p>Asthma Australia use GSK placebo devices alongside other companies' devices in their inhaler technique sessions. In 2018 GSK donated placebo devices to Asthma Australia for use across state-run training programs. This is not an exclusive arrangement between GSK and AA and GSK does not have any input in the development or delivery of these training programs.</p>	\$ 20,306.00
Lung Foundation Australia (COPD)	<p>Support 'Expanding the Lungs in Action Program' for patients with chronic lung disease. The program is an evidence-based intervention of pulmonary maintenance exercise and provides people with chronic lung disease the essential tools to reduce hospital admissions. Lungs in Action classes are delivered by exercise professionals specially trained by Lung Foundation Australia and provides participants with unlimited access to a structured exercise program and connection with peers with similar symptoms and experiences. Lungs in Action also acts a vehicle for promoting disease self-management, symptom awareness and control.</p>	\$ 59,900.00
Lung Foundation Australia (COPD)	<p>Donation of 3,000 Ellipta, 3,000 Accuhaler and 3,000 MDI placebo inhaler devices for LFA's education and training.</p> <p>This training provides clinicians with an interactive session to familiarise themselves with the various inhaler devices for COPD. When a placebo is in a training event it is utilised in a demonstration capacity with a 1:1 attendee:placebo ratio. GSK's placebo devices are included in a pack containing all available COPD inhalers; training demonstrates correct inhaler technique for all devices from all companies. GSK does not have any input in the development or delivery of these training programs.</p> <p>In 2018 the Lung Foundation reached over 2000 GPs, Nurses, and Pharmacists and educated them in correct inhaler device technique through various COPD projects. The inhaler kits and hands-on learning is always well received and of high value to all health professionals that participate in their education.</p>	\$ 40,350.00
Lung Foundation Australia (PAH)	<p>Financial support to provide up-to-date information and education to people impacted by Pulmonary Arterial Hypertension (PAH) and increase awareness of PAH in the community to support early diagnosis. The support covers the cost of the webinar platform, creation of a web page and online booking form for registrations, development of a promotional flyer and a promotional campaign. In addition, the planning and delivery of two PAH specific presentations at the Lung Foundation Australia Education Seminar in Perth &amp; Melbourne (includes flight and accommodation costs).</p>	\$ 15,000.00
Meningitis Centre Australia	<p>Financial support for costs associated with attendance and stall operations at five Pregnancy and Baby Expos across Australia (Adelaide, Sydney, Brisbane, Perth and Melbourne). The aim of the event is to inform parents of the vaccinations which are available for their children to prevent meningococcal disease. In addition, brochures and information kits on the signs, symptoms, strains, vaccinations, adverse effects and recovery from disease to be disseminated.</p>	\$ 20,000.00

Meningitis Centre Australia	Donation of Menveo and Bexsero vaccines for a family of 10.	\$	4,100.00
National Asthma Council Australia	Financial support to review the 'My Asthma Guide' booklet, translate and print 10,000 copies. Support to reprint Written Asthma Action Plans Initial phase support of 'Rethinking Written Asthma Action Plans' project. This publication is based on the Australian Asthma Handbook and is the comprehensive summary of asthma diagnosis and management for people with asthma and their families.	\$	72,700.00
National Asthma Council Australia	Donation of 120 Ellipta, 170 Accuhaler and 170 MDI placebo inhaler devices. The National Asthma Council uses GSK placebo inhalers in an initiative to educate pharmacists on best practice asthma care. GSK inhalers are used alongside inhalers from other companies – this is not an exclusive arrangement with NAC and GSK does not have any input in the development or delivery of these training programs	\$	1,897.00
Pulmonary Hypertension Association Australia	Support for the Pulmonary Hypertension Association Australia (PHAA) Board of Management with \$4,000 for their travel and accommodation costs, assisting PHAA to attend a 'meet and greet' session and conduct the PHAA Members and Carers Day session at PHSANZ ASM with the theme of Engaging high risk population. The topics of the event were Engaging VFR travellers and migrants, Occupationally at risk groups (focus on HCW influenza vaccination) and Challenges of vaccinating the homeless in the hep A outbreaks in California	\$	4,000.00